JAK2 and myeloproliferative neoplasm: In our study, we retrospectively detected the presence of CALR mutations in a cohort of 524 JAK2 V617F-negative patients who presented with clinical and/or laboratory suspicion of MPN with the main goal of determining the diagnostic value of this detection.